ArticleiScience2026
Proteomic profiling identifies prognostic signature for Krukenberg tumor of gastrointestinal origin.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Negative initial endoscopy and 18F-FDG PET/CT may not exclude occult gastric cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Krukenberg tumor (KT) primarily originates from the stomach and colorectum, but reliable biomarkers for distinguishing KT from other tumors at the same sites and predicting ovarian metastasis remain lacking. Using pressure cycling technology (PCT) and data-independent acquisition (DIA) mass spectrometry, we analyzed 263 formalin-fixed paraffin-embedded (FFPE) samples, identifying 10,837 proteins. The results revealed distinct proteomic signatures from the primary gastrointestinal lesions of KT. Comparative analyses identified group-specific pathways, particularly mesenchymal-epithelial transition (MET) signaling pathways and extracellular matrix (ECM) pathways, that were enriched in the primary lesions of KT. We developed protein-based classifiers with promising diagnostic value in distinguishing the primary gastrointestinal lesions of KT from those without ovarian metastases. We depicted distinct proteomic signatures in the primary gastrointestinal lesions of KT and identified potential biomarkers for prediction and early intervention of gastrointestinal cancer patients at risk of ovarian metastases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.